Analysis of acquired mutations for each drug and treatment strategies will be essential, and multiple analyses along the clinical course progression similar to that reported in this study might be required promptly for a better prognosis of patients with ALK‐rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.